Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CCTR
USDCHINA CRESCENT ENTERPRISES INC COM NEW
Last [Tick] $0.0349[+]
Change Up$0.0049
% Change Up16.33%
Bid $0.0347
Bid Size 50
Ask $0.0349
Ask Size 50
Open $0.0349
Volume 10,623,891
Day High $0.035
Day Low $0.0348
Previous Close $0.03
Prev. Close Date 04/15/2010
Silverfusion, sounds like you've done more than your share of homework.
I've been caught in these kinds of deals before. Brilliant scientists with remarkable ideas get tied up with the wrong business partners.
Battling to the end, society loses, investors lose and the scientists lose. Only the business partners come out ahead. What a shame!
Forum closed with nothing from Dean...
Has anyone dared think this could be the sign we've all been waiting for?
Just wondering if others have found this little gem.
Looks like solid growth, generous dividends and nice tax breaks for the patient, long-term investor.
The Road Show Begins
------------------
Hyperdynamics to Present at IPAA Symposium in New York on April 13
Hyperdynamics to Present at IPAA Symposium in New York on April 13
Apr. 7, 2010 (PR Newswire) --
HOUSTON, April 7 /PRNewswire-FirstCall/ -- Hyperdynamics Corporation (NYSE Amex: HDY) announced today that it will present at the IPAA Oil & Gas Investment Symposium New York on Tuesday, April 13. Ray Leonard, President and Chief Executive Officer, is scheduled to present at 8:45 a.m. EDT. Company management will also be hosting a breakfast table from 7:45 a.m. to 8:30 a.m. on both Tuesday, April 13 and Wednesday, April 14 at the conference.
A link to a live audio webcast will be available in the Investor Relations section of Hyperdynamics' website at www.hyperdynamics.com. Listeners should access the site at least 10 minutes prior to the presentation start time. A replay will be available for approximately 30 days.
Here's the link
http://ecoloclean.com/ECCI.pk-15%28c%292-11%20Info-Stmt.pdf
This cost them a few dollars. Maybe, soon, we'll find out why they did it.
Having difficulty downloading presentations and reports from Galaxy site.
Any chance someone could post the authorized share count, outstanding share count and the float.
Much appreciated.
Any ideas on how to connect to today's presentation?
Today's PR is powerful.
These guys exhibit tremendous scientific prowess. But their business naivity scares me.
The "leak" on this board was stupid. The radio interview with a pair of clowns left much to desire. And the early financing choice/business manager choice practically drove this company under.
While I'm at it, after 10+ years in business; with a product line exceeding 650 products; and with worldwide acceptance as a leader in their field, shouldn't we expect a well managed company to show positive cash flow and at least a small profit on their bottom line?
I maintain a substantial holding here because of the opportunity I foresee. But management's lack of business acumen causes me to realize that all could be lost with another bonehead management blunder.
Adama4, you certainly do have an interesting way of expressing yourself.
Any chance you can point me to something that verifies Goldman Sachs has taken a substantial position in HDY?
The little knowledge I have of Goldman suggests that they rarely miss when they take large positions.
It doesn't seem to download. I've been waiting an hour for the download to end and for the play button to appear.
Hmmmmmmmmmmmmmm!
The Children's Internet, Inc. Announces Development of Comprehensive New Web Platform
SACRAMENTO, CA -- (Marketwire) -- 02/26/10 --
The Children's Internet, Inc. (PINKSHEETS: CITC) announced today that it has begun development of a comprehensive new web platform with its strategic alliance partner "IDEAS - The Innovation Studio," based out of Orlando, Florida. IDEAS, formerly part of the Walt Disney Company, will bring their world class pedigree to this project ensuring that this new web platform will be completely interactive and exhibit all of The Children's Internet, Inc. (CITC) and IDEAS' cutting edge technology and design techniques.
The new web platform will provide easy, user friendly access to the many facets of CITC's unique and novel children's internet Wizard Lock Security?, including its Secure-Chat, Secure-Search, Secure-Browse, and Secure-Email. Mr. Lewis stated that, "Having IDEAS help us engineer and produce a new web platform is really exciting and will allow us to provide a special, kid-friendly internet experience that also will be easy for parents to monitor and change."
CITC estimates that the new web platform will debut within 90 days of this release and is designed to correspond with the initial release into the marketplace of its beta Wizard Lock Security? product. Mr. Lewis added that, "The work we are doing now should result in an industry leading web platform that will only serve to enhance and compliment our industry leading children's internet Wizard Lock Security?."
For more information, contact Richard J. Lewis at 916-631-1988 or by email at info@kidwideweb.net . Additional information can also be found at www.kidwideweb.net or www.thechildrensinternetinc.com.
Forward-Looking Statements:
This press release may be deemed to contain "forward-looking statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements are made as of today's date and we do not undertake any obligation to update forward-looking statements. You can identify such statements by our use of such words as "should," "expect," "will," "intends," and similar words and phrases which denote future events and which may depend on the future performance
of the Company.
Specifically, these include statements as to future product releases, the implementation of strategic initiatives and the ownership in TCI upon completion of the transaction and whether or not the transaction will be consummated. Our assumptions underlying these statements are also "forward-looking" statements. Forward-looking statements are based on information and assumptions that are dynamic in nature and subject to rapid and sometimes abrupt changes. Our forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the statements. Our forward-looking statements are also subject to important risks and uncertainties detailed in our latest reports filed with the SEC and available on its website at www.sec.gov.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact Richard J. Lewis 916-631-1988 Email Contact
JJBenzo, many thanks for your investment thesis. You've clearly put a great deal of time and effort into understanding the potential that Arrayit may realize.
Just out of curiosity... have you probed the folks at Arrayit about any prior experience in providing FDA submissions.
More than ever I'm seeing today's FDA as a model of our Government inaction.
Big volume this morning with a nice jump in price. Has the dividend been announced?
Conference Call Summary, please... anyone
Silverfusion, forgive my possible misunderstanding... but in the 12/15/09 8k I thought that Arrayit cleared their past debts through the issuance of shares in full repayment of the debt.
Didn't these shares eliminate the threat of toxic financing agreements?
Chris, thanks for keeping us up to date. Looks like maybe, finally, this story is coming together.
Thanks for the clarification on restricted share count. This company is really a jewel!
I can't imagine what might happen to the few public shares when the first commercial diagnostic is announced and the world realizes where this company is headed.
JJBenzo, any insight on the 20,000,000 authorized preferred shares?
Found it! This is a real gem buried in the cloak of a Doctoral dissertation.
Ownership is solidly in the hands of the few that understand what the company is doing (the board of directors.)
Their current line of 650 products sets an industry standard and is in use worldwide.
And then there's this quote from Dr. Schena:
"We'll continue to offer and grow our life sciences business, but obviously the biggest expansion in terms of revenues will be in the diagnostics and health care space. Part of the reason for our continued interest in the research life sciences space is that by offering our equipment, our instruments, tool kits and reagents to basic researchers, that empowers basic researchers make fundamental scientific discoveries that then become tomorrow's products. And then we can actually license these discoveries back and offer these as commercial diagnostics."
Please put a pointer to the article on this site. I can't find it on the Arrayit site and the Wall Street Transcript requires a subscription.
Thank you.
Yes, its a shell. But someone's pretty serious about wanting to control it.
Any guesses about what tomorrow might bring? These runs usually last more than a day.
IMO,The best we can hope for is that this shell is cleansed and sold to a viable enterprise.
Surprise, surprise!!
All of a sudden we have financials and a substantial insider buy.
New product availability Jan 1st, 2010 along with a committed customer base waiting to employ it!!
Sounds like we're in for a few substantial announcements... and then KABOOM!
I'm beginning to wonder if I even heard the lastest!
OK; I'll bite. What's the latest?
Maybe the FDA has just ground to a halt!!
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm
Best I can see they haven't issued a new device approval since 11/3/09.
Their site isn't even updated to reflect 2010 approvals yet.
Any comments on how the Cal Bay business plan matches up with this one?
http://money.cnn.com/2009/12/08/real_estate/lewie_ranieri_mortgages.fortune/index.htm
Just my opinion, but these late day form t trades could be someone who plans a buyout after approval and is establishing a low price share basis as we wait for approval.
What's his downside? If he is outbid he'll make a huge profit on the shares he's now accumulating.
It may take a day or two for your account to properly show the reverse split. But it is a 1 for 10; so each 100 old shares will become 10 new shares. I'm not sure what the new symbol will be.
Try FTWRD for the post reverse split shares.
They're executing a 1 for 10 reverse split.
"Called China US Bridge Capital Limited. As you know, one of the biggest stakeholders in CHFI.
I'm buying more today!!!"
Sounds encouraging. When will we see a report/announcement/filing?
Caiostro, many thanks for your dd on CHFI.
"Don't forget, it's an OTCB listed company. They needn't to file every quarter."
Perhaps you have also found out when CHFI is required to file?
Glen, here are two lesser known ideas:
XING - Major assets here. Big time telephone co selling off low end (unprofitable) portion of business and transitioning into natural resources (mining.)
ONBI - American Management Team quickly amassing multiple Chinese companies that utilize green processes to produce raw chemicals, herbal extracts, natural health suppliments and organic products.
It might also be interesting to get your perspective on the mia company - CHFI
Whatever those numbers were... they're not "Devices"
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm
NKBP Began trading today.
Insights?
Achievements & Honors
On January 2009
Nuokang Bio-pharmaceutical was short-listed on “Forbes China most potential small and medium- sized enterprises 2009”.
On December 2008
Penglai Nuokang Bio-pharmaceutical Co. Ltd. was accredited as New-high Technology Corporation by Science and Technology Department of Shandong Province.
On December 2008
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was accredited as New-high Technology Corporation by Science and Technology Department of Liaoning Province.
On December 2008
Nuokang Bio-phaemaceutical was honored as “2008 China Most Potential Development Healthcare Enterprises” in the Third China Healthcare Industry Investment Summit.
On November 2008
The Hemocoagulase Atrox for Injection project, which was researched and developed by Liaoning Nuokang Bio-pharmaceutical Co., Ltd., was honored as Shenyang Revitalization of Science & Technology Development Award by Shenyang Municipal Government.
On March 2008
Liaoning Nuokang Bio-pharmaceutical Co., Ltd. was honored as “Good Employee Relation Enterprise of Shenyang City”.
On Janruary 2008
Penglai Nuokang Pharmaceutical Co., Ltd. was honored as “Good Employee Relation Enterprise of Yantai City”.
On December 2007
As strategic investors, Sequoia Capital China Fund, and HBM BioMed China invested USD17 million in Nuokang Group.
On August 2007
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was awarded as “Province Level Enterprise Technique Center” by Economic Committee of Liaoning Province.
On August 2007
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was accredited as “Post Doctor Science and Research Working Station” by Human Resource Bureau of Shenyang City.
On April 2006
The Hemocoagulase product of Liaoning Nuokang Bio-pharmaceutical Co., Ltd. won the Shenyang Municipal Second-class Award of Science and Technology Progress Prize.
On October 2005
Penglai Nuokang Pharmaceutical Co., Ltd. was evaluated as Grow-up Enterprise of Shandong Province.
On November 2003
Hemocoagulase Research project of Shenyang Sainuo Science & technology Development Co., Ltd. won the Third-class Award of Science and Technology Progress Prize of Liaoning Province.
Achievements & Honors
On January 2009
Nuokang Bio-pharmaceutical was short-listed on “Forbes China most potential small and medium- sized enterprises 2009”.
On December 2008
Penglai Nuokang Bio-pharmaceutical Co. Ltd. was accredited as New-high Technology Corporation by Science and Technology Department of Shandong Province.
On December 2008
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was accredited as New-high Technology Corporation by Science and Technology Department of Liaoning Province.
On December 2008
Nuokang Bio-phaemaceutical was honored as “2008 China Most Potential Development Healthcare Enterprises” in the Third China Healthcare Industry Investment Summit.
On November 2008
The Hemocoagulase Atrox for Injection project, which was researched and developed by Liaoning Nuokang Bio-pharmaceutical Co., Ltd., was honored as Shenyang Revitalization of Science & Technology Development Award by Shenyang Municipal Government.
On March 2008
Liaoning Nuokang Bio-pharmaceutical Co., Ltd. was honored as “Good Employee Relation Enterprise of Shenyang City”.
On Janruary 2008
Penglai Nuokang Pharmaceutical Co., Ltd. was honored as “Good Employee Relation Enterprise of Yantai City”.
On December 2007
As strategic investors, Sequoia Capital China Fund, and HBM BioMed China invested USD17 million in Nuokang Group.
On August 2007
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was awarded as “Province Level Enterprise Technique Center” by Economic Committee of Liaoning Province.
On August 2007
Liaoning Nuokang Bio-pharmaceutical Co. Ltd. was accredited as “Post Doctor Science and Research Working Station” by Human Resource Bureau of Shenyang City.
On April 2006
The Hemocoagulase product of Liaoning Nuokang Bio-pharmaceutical Co., Ltd. won the Shenyang Municipal Second-class Award of Science and Technology Progress Prize.
On October 2005
Penglai Nuokang Pharmaceutical Co., Ltd. was evaluated as Grow-up Enterprise of Shandong Province.
On November 2003
Hemocoagulase Research project of Shenyang Sainuo Science & technology Development Co., Ltd. won the Third-class Award of Science and Technology Progress Prize of Liaoning Province.
Homepage > About Nuokang > Company Profile
China Nuokang Bio-Pharmaceutical Inc. is a leading, fully integrated, profitable biopharmaceutical company focused on researching, developing, manufacturing and marketing hematological and cardiovascular products. We sell a portfolio of fourteen products, which includes principal products Baquting®, a flagship hemocoagulase, and Aiduo®, a cardiovascular stress imaging agent. Our product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.
Developed in-house and launched in 2001, Baquting, our flagship product, is China''''s leading hemocoagulase for the treatment or prevention of bleeding. Through September 30, 2009, we had sold an aggregate of over 38 million units of Baquting to our end-customer base of over 2,400 hospitals across China.
Our end-customer base includes approximately 80% of the Class 3A hospitals in major Chinese cities. Our sales force consisted of 24 direct sales offices with 300 sales personnel, complemented by 16 third-party marketing agents with over 200 sales personnel. We employ a physician-targeted marketing model, and our sales and marketing activities receive strong academic support from a specialist network comprising approximately 100 national key opinion leaders and physicians in various clinical areas.
If you're going to consider LGAL in play; I suggest you do the same with its sister company ADMH.
LGAL is changing their symbol to UNSR.
ADMH will be merged into UNSR.
ADMH will become UNSR.
Right now, the new technology and the boat are both owned by ADMH.
p.s., great board. Much appreciated.
Private insights much appreciated. Now CBAY's sounding tempting.
Thanks again.